31 August to 4 September, 2019 in Paris, France
The Hot Line Press Programme is announced today: six Hot Line press conferences with 27 trials presented, bringing reporters the latest research in cardiology.
Hot Line 1:
- THEMIS: use of dual antiplatelet therapy in patients with diabetes and stable coronary artery disease.
- THEMIS-PCI: ticagrelor in patients with diabetes and stable coronary artery disease with a history of prior percutaneous coronary intervention.
- PARAGON-HF: is angiotensin receptor neprilysin inhibition beneficial in heart failure with preserved ejection fraction?
- COMPLETE: does complete revascularisation reduce hard clinical outcomes in patients with ST-segment elevation myocardial infarction?
Hot Line 2:
- NZOTACS: use of oxygen therapy in acute coronary syndromes.
- CONDI-2/ERIC-PPCI: limb remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
- ISAR-REACT 5: is ticagrelor superior to prasugrel in acute coronary syndrome patients with a planned invasive strategy?
- HiSTORIC: impact of a rapid rule out pathway to risk stratify patients with suspected acute coronary syndrome.
Hot Line 3:
- Combined effect of lower low-density lipoprotein (LDL) cholesterol and lower systolic blood pressure on the lifetime risk of cardiovascular disease.
- AFIRE: comparison of anticoagulant monotherapy versus dual therapy with an antiplatelet in patients with atrial fibrillation and stable coronary artery disease.
- GALACTIC: trial of early goal-directed therapy versus standard care in acute heart failure.
- Salt substitution: impact of a population-wide strategy to reduce blood pressure.
- HOPE 4: risk factor control in hypertensive patients in Columbia and Malaysia.
Hot Line 4:
- BB-meta-HF: use of beta-blockers in patients with heart failure and renal dysfunction
- SYNTAXES: 10-year survival after coronary artery bypass grafting versus percutaneous coronary intervention.
- MITRA-FR: 2-year outcomes after percutaneous mitral valve repair in patients with heart failure and severe secondary mitral regurgitation.
- DANAMI-2: 16-year follow-up after primary percutaneous coronary intervention versus fibrinolysis in ST-segment elevation myocardial infarction.
Hot Line 5:
- CLARIFY: 5-year registry results in more than 32,000 patients with stable coronary artery disease in 45 countries.
- SWEDEHEART: secondary prevention medication and long-term mortality after coronary artery bypass surgery.
- ICD use in HF: 5-year mortality in heart failure patients with an implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
- FRANCE-TAVI: propensity-matched comparison of balloon- versus self-expandable heart valves on outcomes in aortic stenosis patients undergoing transcatheter aortic valve implantation.
- PURE: trends in cardiovascular disease, cancer, and related mortality in high- versus low-middle income countries.
- PURE: influence of modifiable risk factors on cardiovascular disease and mortality in 21 countries.
Hot Line 6:
- Rapid-TnT: randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes.
- ENTRUST-AF PCI: choice of antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation.
- POPular Genetics: genotype-guided oral P2Y12 inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- DAPA: long-term outcome of implantable defibrillator early after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Professor Sarah Clarke, Chairperson of the ESC Media Committee, said: “This is the research that can change clinical practice, give insights into controversial issues, and provide a contemporary picture of trends in treatments and outcomes across the globe.”
Sophia Antipolis, 9 July 2019
Notes to editors
The Opening Press Conference on Saturday 31 August at 10:00 CEST will be live streamed on Periscope.
The Twitter hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress.
Journalists are invited to become accredited and register here.
French speaking media are welcome to contact the local agency for the 2019 congress, LauMa Communication:
Press releases will be available here when the embargo lifts. Embargoed press releases will be available on an exclusive web page (for on-site press). No paper versions will be available but there will be e-printers in the Press Working Area.
For photos or interview requests, please contact [email protected]
For all studies, including late breaking science, the embargo is lifted at the start of the scientific session in which the presentation/study is scheduled.
Please check the ESC filming and recording policy in the ESC Media and Embargo policy.
About ESC Congress
ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France.
Explore the scientific programme and press conference programme.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
ESC Press Office